Breaking News, Collaborations & Alliances

GSK, Unigene in Osteoporosis Pact

New agreement covers API, formulation for oral PTH trial

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

GlaxoSmithKline and Unigene Laboratories have entered into a development services and clinical supply agreement. Unigene will receive as much as $2.2 million in milestone payments from GSK to undertake certain development and manufacturing activities related to the API and finished drug product for an oral formulation of a recombinantly produced investigational parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women in advance of GSK’s potential decision to stu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters